{
    "organizations": [],
    "uuid": "0e7fac4c907c311f262d62fc1fee80146805836d",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/02/globe-newswire-dynavax-to-host-first-quarter-2018-financial-results-conference-call.html",
    "ord_in_thread": 0,
    "title": "Dynavax to Host First Quarter 2018 Financial Results Conference Call",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "BERKELEY, Calif., Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018, and host a conference call that day to review the results and provide a business update at 4:30pm ET/1:30pm PT.\nTo access the call, participants must dial (866) 548-4713 in the U.S. or (323) 794-2093 internationally, and use the conference ID 8635193. The live call will be webcast and can be accessed in the \"Investors and Media\" section of the company's website at www.dynavax.com . A replay of the webcast will be available for 30 days following the live event.\nA replay of the conference call will be available for two weeks and can be accessed by dialing (844) 512-2921 in the U.S. or (412) 317-6671 internationally. The conference ID for the replay will be 8635193.\nAbout Dynavax\nDynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com .\nContact:\nDavid Burke\nDirector, IR & Corporate Communications\n510.665.7269\ndburke@dynavax.com\nSource:Dynavax Technologies Corporation",
    "published": "2018-05-03T00:15:00.000+03:00",
    "crawled": "2018-05-03T02:16:13.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "berkeley",
        "dynavax",
        "technology",
        "corporation",
        "nasdaq",
        "dvax",
        "today",
        "announced",
        "report",
        "financial",
        "result",
        "first",
        "quarter",
        "ended",
        "march",
        "market",
        "close",
        "tuesday",
        "may",
        "host",
        "conference",
        "call",
        "day",
        "review",
        "result",
        "provide",
        "business",
        "update",
        "pt",
        "access",
        "call",
        "participant",
        "must",
        "dial",
        "internationally",
        "use",
        "conference",
        "id",
        "live",
        "call",
        "webcast",
        "accessed",
        "investor",
        "medium",
        "section",
        "company",
        "website",
        "replay",
        "webcast",
        "available",
        "day",
        "following",
        "live",
        "event",
        "replay",
        "conference",
        "call",
        "available",
        "two",
        "week",
        "accessed",
        "dialing",
        "internationally",
        "conference",
        "id",
        "replay",
        "dynavax",
        "dynavax",
        "biopharmaceutical",
        "company",
        "focused",
        "leveraging",
        "power",
        "body",
        "innate",
        "adaptive",
        "immune",
        "response",
        "receptor",
        "tlr",
        "stimulation",
        "dynavax",
        "discovers",
        "develops",
        "novel",
        "vaccine",
        "therapeutic",
        "company",
        "first",
        "commercial",
        "product",
        "hepatitis",
        "b",
        "vaccine",
        "recombinant",
        "adjuvanted",
        "approved",
        "united",
        "state",
        "dynavax",
        "lead",
        "immunotherapy",
        "product",
        "investigational",
        "cancer",
        "immunotherapeutic",
        "currently",
        "evaluated",
        "phase",
        "study",
        "second",
        "cancer",
        "immunotherapeutic",
        "dv281",
        "phase",
        "development",
        "information",
        "visit",
        "contact",
        "david",
        "burke",
        "director",
        "ir",
        "corporate",
        "communication",
        "dburke",
        "source",
        "dynavax",
        "technology",
        "corporation"
    ]
}